Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN AND SULBACTAM versus PENTIDS 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN AND SULBACTAM versus PENTIDS 250.
AMPICILLIN AND SULBACTAM vs PENTIDS '250'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity. Sulbactam is a β-lactamase inhibitor that irreversibly inhibits a broad range of β-lactamases, preventing degradation of ampicillin.
Penicillin G binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting transpeptidase activity and cell wall synthesis, leading to bacterial lysis.
1.5-3 g (ampicillin 1-2 g + sulbactam 0.5-1 g) IV/IM every 6 hours. Maximum daily dose of sulbactam is 4 g.
250 mg orally every 8 hours.
None Documented
None Documented
Ampicillin: 1-1.8 hours; sulbactam: 1-1.5 hours. Prolonged in renal impairment (e.g., creatinine clearance <30 mL/min: up to 8-12 hours).
0.5-1 hour (prolonged in renal impairment; requires dose adjustment when CrCl <30 mL/min)
Primarily renal (70-75% unchanged ampicillin, 75-80% unchanged sulbactam). Biliary excretion accounts for ~25% of ampicillin and ~20% of sulbactam. Fecal elimination is minor (<5%).
Primarily renal (60-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal (10-30%)
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic